Full text is available at the source.
Abstract
The safety of GLP-1 receptor agonists in patients with a history of pancreatitis is uncertain.
- GLP-1 receptor agonists are commonly prescribed for type 2 diabetes and obesity.
- The review focuses on the risk of recurrent acute pancreatitis in patients using these medications.
- Current evidence regarding the association between GLP-1 RA therapy and recurrent acute pancreatitis is limited.
- Further evaluation is necessary to clarify the safety of GLP-1 RAs in individuals with prior pancreatitis.
Simplified